Standardized Echinacea Product Shown to Reduce Severity and Duration of Cold and Flu

Study by Factors Group R & D Technologies Published in UK Health Journal

VANCOUVER, BC – Canadian-based Company, Factors R & D Technologies Ltd., has achieved a breakthrough as a science and research company. The Company has definitively proven that its standardized Echinacea product – ECHINILIN® -- reduces the severity and duration of cold and flu symptoms.

A British journal has published the Company’s clinical trial results by its science team regarding the early intervention with an Echinacea purpurea preparation, ECHINILIN, for effectively treating the common cold. Focus on Alternative and Complementary Therapies (also known as FACT) reviewed the Phase II clinical trial results in the September issue of its quarterly publication.

According to the review, as published on the FACT site (, the Factors R & D Science team was “the first to use a standardized Echinacea extract (alkamides, cichoric acid and polysaccharides) to demonstrate statistically significant evidence of consistent effectiveness against naturally acquired cold viruses.

Dr. Richard Barton, Department of Biochemistry and Molecular Biology at the University of British Columbia and co-director of the human clinical studies says, “We saw a sustained increase in nature killer cells (NK cells) in participants when they were given ECHINILIN which no doubt contributed to a more active immune system resulting in the destruction of virus-infected cells.”

“The end result was a remarkably high reduction in both severity of symptoms and duration of the infection,” says Dr. Barton.

Dr. Barton says, “There have been numerous studies examining the immune-modifying potential of Echinacea preparations. But none, to my knowledge, have used a standardized extract”.

He says that the rationale for the standardization, selected component ratios and dosing levels for Echinacea products are further supported by the conclusive results obtained in this particular clinical trial.

This is the second published study for Dr. Barton and his team. The Journal of Clinical Pharmacy and Therapeutics published an article on Dr. Barton’s study earlier this year.

Estimates suggest that colds and flu affect approximately 72 per cent of Canadians each year. It is believed that the social costs surrounding the common cold are at least $400-million per year which makes it more costly than asthma, congestive heart failure and chronic obstructive pulmonary disease combined. Visit our website at

Factors R & D Technologies Ltd. is Canada’s leading research organization in evidence-based phytopharmaceuticals. The Company’s science team is comprised of international experts in their field—some of whom hold positions at universities in Alberta, British Columbia, Dalhousie, and Toronto in Canada and in Graz in Austria. Factors R & D coordinates all research and development of the 500-plus products for the Factors Group. Research projects include the agronomy of herbal and other medicinal plants, organic farming methods, extraction processes, laboratory testing and human clinical trials.


Factors R & D Technologies Ltd.

Kate Jobling
Direct: 604-415-4181
Email: [email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.